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bstract
Aim.  –  This study explored the association of depressive symptoms with indices of insulin sensitivity and insulin secretion in a cohort of
on-diabetic men and women aged 30 to 64 years.
Methods.  –  The study population was derived from the 3-year follow-up of the Relationship between Insulin Sensitivity and Cardiovascular
isease Risk (RISC) study. Presence of significant depressive symptoms was defined as a Center for Epidemiologic Studies Depression Scale
CES-D) score ≥  16. Standard oral glucose tolerance tests were performed. Insulin sensitivity was assessed with the oral glucose insulin sensitivity
OGIS) index. Insulin secretion was estimated using three model-based parameters of insulin secretion (beta-cell glucose sensitivity, the potentiation
actor ratio, and beta-cell rate sensitivity).
Results.  –  A total of 162 out of 1027 participants (16%) had significant depressive symptoms. Having significant depressive symptoms was
ot related to either OGIS [standardized beta () −0.033; P  = 0.24] or beta-cell glucose sensitivity (  −0.007; P  = 0.82). Significant depressive
ymptoms were related to decreased beta-cell rate sensitivity (odds ratio for significant depressive symptoms of the lowest vs. highest quartile of
eta-cell rate sensitivity was 2.04; P  = 0.01). Also, significant depressive symptoms were associated with a statistically significant decrease in the
otentiation factor ratio in unadjusted models, but not in the fully adjusted model.
Conclusion.  –  Depressive symptoms were not related to insulin sensitivity and tended to be weakly associated to some parameters of insulin
ecretion in non-diabetic individuals. Prospective studies are needed to study the temporal association between depression and insulin secretion.
 2012 Elsevier Masson SAS. All rights reserved.eywords: Depression; Diabetes; Insulin sensitivity; Insulin secretion
ésumé
sécrétion dans l’étude de cohorte RISC.Présence de symptômes de dépression, insulinosensibilité et insulino
But.  –  Explorer l’association entre la présence de symptômes dépressifs et des indices de l’insulinosensibilité et de l’insulinosécrétion dans une
ohorte d’hommes et de femmes non diabétiques, âgés de 30 à 64 ans.
Méthodes.  –  La population étudiée est issue du suivi à trois ans de la cohorte Relationship between Insulin sensitivity and Cardiovascular risk
RISC). La présence de symptômes dépressifs significatifs a été définie par un Center for Epidemiologic Studies Depression Scale (CES-D) avec
n score supérieur ou égale à 16. Un test d’hyperglycémie provoquée par voie orale a été réalisé, l’insulinosensibilité a été évaluée par l’indice Oral
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lucose Insulin sensitivity (OGIS) et l’insulinosécrétion a été estimée à partir de trois modèles (sensibilité des cellules bêta au glucose, facteur de
otentialisation, et sensibilité des cellules bêta).
Résultats.  –  Cent soixante-deux des 1027 participants (16 %) présentaient des symptômes dépressifs significatifs. La présence de symptômes
épressifs significatifs n’était pas liée à l’insulinosensibilité déterminée par l’indice OGIS (bêta standardisé [] −0,033, P  = 0,24), ni à la sensibilité
es cellules bêta au glucose (  −0,007, P  = 0,82). La présence de symptômes dépressifs significatifs étaient liée à une diminution de la sensibilité des
ellules bêta (l’odds  ratio  du quartile le plus élevé par rapport au quartile inférieur de la sensibilité des cellules bêta pour la présence de symptômes
épressifs importants OR 2,04, P  = 0,01). Enfin, la présence de symptômes dépressifs importants était associée à une diminution statistiquement
ignificative du facteur de potentialisation dans le modèle non ajusté, mais non dans le modèle ajusté.
Conclusion.  –  La présence de symptômes de dépression n’est pas liée à l’insulinosensibilité, mais est faiblement liée à certains paramètres de
’insulinosécrétion chez les personnes non diabétiques. Des études prospectives sont nécessaires pour étudier l’association temporelle entre la
épression et la sécrétion de l’insuline.
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.  Introduction
Depression is commonly seen in diabetes. A meta-analysis
howed that the prevalence of depression (measured as sig-
ificant depressive symptoms or clinical depression) is almost
oubled in individuals with type 2 diabetes compared with those
ithout diabetes (17.6% vs. 9.8%) [1]. Depression is frequently
onsidered a condition that results from the daily burden of hav-
ng diabetes. However, other studies show that depression in
urn is an independent risk factor for the development of type
 diabetes [2]. Recently, Mezuk et al. [3] showed in their meta-
nalysis that depression was associated with a 60% increased
isk of future type 2 diabetes, while Nouwen et al. [4] showed
hat type 2 diabetes was related to a 24% increased risk of future
epression. Several interconnected mechanisms have been pro-
osed by which depression could accelerate the onset of type
 diabetes, including increased hypothalamic–pituitary–adrenal
HPA) axis activity, increased low-grade inflammation [5,6],
mpaired intake or metabolism of omega-3 polyunsaturated fatty
cids [7,8] and visceral obesity [9]. In addition, it has been
uggested that depression-associated insulin resistance (DAIR)
ould account for the increased risk of type 2 diabetes related
o depression [10]. Several studies have shown that depressive
ymptoms are associated with greater insulin resistance [11–15].
ecently, it was reported that young adults with a depressive
isorder formally diagnosed by the Composite International
iagnostic Interview (CIDI) were more insulin-resistant [16].
owever, other studies have not observed a significant rela-
ionship between depressive symptoms and insulin resistance
r even found a negative relationship [17–20].
Both insulin sensitivity and insulin secretion are indepen-
ent predictors of worsening glucose tolerance, which can
ead to diabetes [21]. In addition to reduced insulin sensitiv-
ty, reduced insulin secretion by the pancreatic beta cells may
lso explain part of the increased diabetes risk associated with
epression. Although several studies have focused on the rela-
ionship of depression with insulin sensitivity, less is known
f its relationship with insulin secretion. Holt et al. observed
o significant associations between depressive symptoms and
omeostatic model assessment for insulin secretion (HOMA-
) in a population-based study [22]. In another study, the acute




tas increased in patients with depression compared with con-
rols [23].
To further improve our knowledge of the mechanisms that
ink depression and diabetes incidence, the associations between
epressive symptoms and indices of (1) insulin sensitivity and
2) insulin secretion were examined in a large, relatively healthy,
uropean cohort of men and women aged 30 to 64 years.
. Methods
The study population was derived from the 3-year follow-up
f the Relationship between Insulin sensitivity and Cardiovas-
ular Disease Risk (RISC) study, a prospective observational
ohort study of relatively healthy individuals. The design, pro-
ocol and purpose of the RISC study have been described
lsewhere [24]. Briefly, 1326 clinically healthy Caucasian peo-
le aged 29 to 61 years were recruited at 19 centres in 14
uropean countries. Each centre had its local ethics commit-
ee approval and all participants gave their written informed
onsent to participate. Exclusion criteria were the presence of
hronic diseases and overt cardiovascular diseases and/or treat-
ent for obesity, hypertension, lipid disorders and diabetes.
n addition, those with blood pressure ≥  140/90 mmHg, total
holesterol ≥  7.8 mmol/L, triglycerides ≥  4.6 mmol/L, fasting
lucose ≥  7.0 mmol/L and 2-h glucose ≥  11.1 mmol/L were
xcluded. Baseline assessments were collected between 2002
nd 2005. After 3 years, follow-up measurements were taken in
085 participants. Depressive symptoms were first assessed at
his time point. Cross-sectional data from the 3-year follow-up
ere used in the present report.
.1. Protocol
At the 3-year follow-up, demographic and lifestyle character-
stics were assessed by questionnaire. In addition, participants
ere invited to the study centre for anthropometric measure-
ents and blood sampling. Participants underwent a 75 g oral
lucose tolerance test (OGTT) after an overnight fast. Blood
amples were taken before and during the test at 0, 30, 60, 90
nd 120 min. Patients who self-reported the use of medication
or diabetes were excluded from the present analyses (n  = 5), as
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umber of psychoactive drugs being taken by each participant
as recorded.
.2. Depressive  symptoms
At the 3-year follow-up, depressive symptoms were assessed
y the Centre for Epidemiologic Studies Depression scale (CES-
) [25], a validated 20-item self-reported depression scale that
as good psychometric properties across several populations
25,26]. Individuals completed the CES-D in their native lan-
uage. Items in the scale refer to the frequency of depressive
ymptoms over the last 7 days. The total possible score ranges
rom 0 to 60, with higher scores reflecting more depressive
ymptoms. The CES-D cut-off score of ≥  16 was used to dis-
inguish those with significant depressive symptoms from the
on-depressed persons [25]. For participants who were missing
our or fewer items (n  = 68), the missing scores were assigned
he value of the mean score of the completed items for that
articipant.
.3. Insulin  sensitivity
As a measure of insulin sensitivity, the oral glucose insulin
ensitivity (OGIS) index was calculated. This model-based
ethod for assessing insulin sensitivity uses OGTT-derived glu-
ose and insulin concentrations at 0, 90 and 120 min [27]. The
GIS is a dynamic surrogate measure of insulin sensitivity that
as been validated against euglycaemic clamp data (Pearson’s
orrelation r  = 0.7) [27]. Furthermore, as a secondary outcome,
he inverse of fasting insulin (1/fasting insulin) was also used to
ssess insulin sensitivity. In healthy individuals, 1/fasting insulin
s a well-accepted proxy for insulin sensitivity [28].
.4.  Insulin  secretion
While insulin sensitivity can reliably be estimated in  vivo,
easurement of insulin secretion is more complicated. It has
een advocated that beta-cell functioning cannot be reduced
o a single value, but should instead be assessed by multiple
odel-based insulin secretion parameters [29]. Therefore, three
odel-based parameters of beta-cell function (beta-cell glucose
ensitivity, the potentiation factor ratio and beta-cell rate sen-
itivity) were calculated according to a previously described
odel [30,31]. This model describes insulin secretion as the
um of two components.
The first component represents the dependence of insulin
ecretion on absolute glucose concentration at any time point
uring the OGTT through a dose–response function. The vari-
ble that describes this dose–response relationship is termed
beta-cell glucose sensitivity” and is defined as the mean slope
ver the observed glucose range. The dose–response relation-
hip is modulated by the potentiation factor, which accounts
or the higher insulin secretion during the descending phase of
yperglycaemia than during the ascending phase with the same
lucose concentration during acute stimulation. It is set as a
ositive function of time and to average one during the OGTT.
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ecretion response to glucose. The potentiation parameter used
n the present analysis is the ratio of the potentiation factor at
he end of the 2-h OGTT to the one at the start.
The second component of insulin secretion represents the
ynamic dependence of insulin secretion on the rate of change
n glucose concentration. This component is termed “beta-cell
ate sensitivity” and represents early insulin release.
As a secondary classical outcome for insulin secretion, the
nsulinogenic index was determined as the ratio of the increment
n insulin concentration divided by the increment in glucose
oncentration during the first 30 min of the OGTT: (Insulin
0 min – Insulin 0 min)/(Glucose 30 min − Glucose 0 min) [32].
.5. Covariates
Gender and age were derived from the demographic ques-
ionnaires. The centre of recruitment was registered for each
articipant. Smoking status (never, smoker, ex-smoker) and
lcohol intake (g/day) were assessed through items on the
ifestyle questionnaire. Physical activity was assessed with the
ull version of the International Physical Activity Questionnaire
IPAQ), which has been validated for international studies [33].
ts questions refer to physical activity over the past 7 days. Using
he scoring system available online at www.ipaq.ki.se, the level
f physical activity for each participant was classified as either
nactive, minimally active or health-enhancing.
.6. Analytical  methods
Blood samples were separated into plasma and serum,
ivided into aliquots and stored at −80 ◦C for glucose, insulin
nd C-peptide determination. Samples were transported on dry
ce at prearranged intervals to central laboratories. Plasma glu-
ose was measured using the glucose-oxidase technique. Serum
nsulin was measured by a specific time-resolved immunoflu-
rometric assay (AutoDELFIA insulin kit, Wallac Oy, Turku,
inland), with the following assay characteristics: sensitivity
–2 pmol/L; within-assay variation 5%; and between-assay vari-
tion 5%.
.7. Statistical  analysis
The demographic and clinical characteristics were compared
etween participants with significant depressive symptoms and
hose without significant symptoms. Continuous variables were
ompared using independent t  tests and categorical variables
sing Chi2 tests. Linear regression analyses were performed
ith significant depressive symptoms as predictors and the
wo insulin sensitivity measures (OGIS and logarithmically
ransformed 1/fasting insulin) as outcome variables. Potential
onfounders (gender, age, centre) and potential behavioral medi-
tors (smoking status, alcohol intake and physical activity) were
dded to the linear regression model in a stepwise approach.
ikewise, linear regression analyses were performed with the
ogarithmically transformed indices of insulin secretion (beta-
ell glucose sensitivity, potentiation factor ratio, beta-cell rate
ensitivity and insulinogenic index) as outcome variables. In
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Table 1
Characteristics of depressed versus non-depressed participants in the 3-year follow-up of the RISC study (n = 1027).
Non-depressed (n = 865) Depressed (n = 162) P
Women 446/865 (51.6%) 113/162 (69.8%) < 0.001
Smoking status
Never 408/857 (47.6%) 64/158 (40.5%) < 0.001
Smoker 162/857 (18.9%) 52/158 (32.9%)
Ex-smoker 287/857 (33.5%) 42/158 (26.6%)
IPAQ score 0.034
Inactive 190/862 (22.0%) 42/157 (26.8%)
Minimally active 325/862 (37.7%) 69/157 (43.9%)
Health-enhancing physical activity 347/862 (40.3%) 46/157 (29.3%)
IFG or IGTa 142/850 (16.7%) 33/160 (20.6%) 0.230
Use of psychoactive drugs 34/819 (4.2%) 21/153 (13.7%) < 0.001
Mean (SD) Mean (SD) P
Age (years) 47.7 (8.3) 48.9 (7.9) 0.098
Body mass index (kg/m2) 25.7 (4.1) 26.0 (4.4) 0.406
Systolic blood pressure (mmHg) 121 (15) 119 (15) 0.172
Median (IR) Median (IR) P
Alcohol intake (g/week) 53 (15–105) 35 (0–78) 0.004b
OGIS (mL min−1 kg lean body mass−1) 10.9 (9.2–12.8) 10.8 (9.4–12.8) 0.406b
1/fasting insulin (pmol L−1) 0.032 (0.022–0.045) 0.032 (0.023–0.046) 0.599b
Beta-cell glucose sensitivity (pmol min−1 m−2 mM−1) 111.3 (80.6–159.7) 107.6 (72.6–154.6) 0.357b
Beta-cell rate sensitivity (pmol m−2 mM−1) 2.96 (2.59–3.21) 2.87 (2.43–3.11) 0.012b
Potentiation factor ratio 1.68 (1.17–2.46) 1.50 (1.11–2.07) 0.045b
Insulinogenic index 76.9 (49.6–117.3) 67.5 (42.4–106.6) 0.021b









































wa IFG defined as fasting plasma glucose (FPG) ≥ 6.1 mmol/L and < 7.0 mmol
b Mann–Whitney U test.
ddition to the previously stated covariates, 1/fasting insulin
as added as a covariate when the insulinogenic index was
tudied to adjust for the prevailing level of insulin sensitivity.
he other reported insulin-secretion variables are considered to
e independent of insulin sensitivity [34], so no adjustments
ere made for insulin sensitivity to those indices. For all linear
egression models except beta-cell rate sensitivity, assumptions
egarding normality of residuals were met. For this reason,
ate sensitivity was categorized into quartiles, and multinom-
nal regression analyses was used with the lowest quartile as
he reference category. In the analysis with rate sensitivity, there
as no adjustment for centre due to the risk of statistical over
tting.
In addition, several sensitivity analyses were conducted. The
bove-mentioned linear regression analyses were repeated:
using continuous CES-D scores instead of the binary CES-D
cut-off;
 after excluding participants who used psychoactive drugs and;
 after excluding participants with fasting plasma glucose ≥
7.0 mmol/L and/or 2-h plasma glucose ≥  11.1 mmol/L.Although such raised values indicate diabetes, these were
nly single assessments of plasma glucose, whereas elevated
evels should be confirmed on multiple occasions before diag-
osing diabetes [35]. Furthermore, to investigate the possibility
b
t
tT defined as 2-h plasma glucose ≥ 7.8 mmol/L and < 11.1 mmol/L.
f a non-linear relationship between depressive symptoms
nd insulin sensitivity/secretion, gender-stratified quartiles were
onstructed for each insulin sensitivity/secretion parameter.
hese quartiles were then combined and used to compare the
revalence of significant depressive symptoms in each quartile.
earson’s Chi2 tests and the Mantel–Haenszel linear-by-linear
ssociation test were used to test differences in the prevalence
f depression between quartiles. All analyses were performed
sing PASW version 17.0 statistics software. A two-tailed P
alue < 0.05 was considered statistically significant.
. Results
Of the 1027 subjects who completed the CES-D, 162 (16%)
ere identified as having significant depressive symptoms and
65 (84%) were non-depressed. The demographic, behavioral
nd medical characteristics of the sample are presented in
able 1, stratified by depressive status. Those with significant
epressive symptoms more often were women, smokers, less
hysically active and consumed less alcohol per week compared
ith the non-depressed subjects. No differences were observed
ith regard to age, body mass index and systolic blood pressure
etween participants with significant depressive symptoms and
hose without.
Table 2 shows the results of the linear regression analysis with
he OGIS and log 1/fasting insulin. There was no statistically
46 M. Bot et al. / Diabetes & Metabolism 39 (2013) 42–49
Table 2
Linear regression analyses of the association of depression with two insulin sensitivity measures: oral glucose insulin sensitivity (OGIS) index and 1/fasting insulin.
Outcome Depression Ba (95% CI)  P
OGIS (n = 937)
Unadjusted 0.273 (−0.229, 0.775) 0.035 0.286
Model 1 −0.232 (−0.685, 0.221) −0.030 0.315
Model 2 −0.188 (−0.628, 0.251) −0.024 0.401
Model 3 −0.286 (−0.717, 0.145) −0.037 0.194
Model 4 −0.300 (−0.736, 0.135) −0.038 0.176
Model 5 −0.301 (−0.737, 0.136) −0.038 0.177
Model 6 −0.262 (−0.695, 0.172) −0.033 0.237
1/fasting insulinb (n = 954)
Unadjusted 0.008 (−0.033, 0.050) 0.013 0.692
Model 1 −0.003 (−0.045, 0.038) −0.005 0.881
Model 2 −0.003 (−0.044, 0.039) −0.004 0.906
Model 3 0.007 (−0.036, 0.049) 0.010 0.762
Model 4 0 (−0.042, 0.043) 0 0.997
Model 5 −0.002 (−0.044, 0.041) −0.003 0.938
Model 6 0.003 (−0.039, 0.046) 0.005 0.874
Model 1: adjusted for gender; Model 2: adjusted for gender and age; Model 3: adjusted for gender, age and centre; Model 4: adjusted for gender, age, centre and
smoking status; Model 5: adjusted for gender, age, centre, smoking status and alcohol intake; Model 6: adjusted for gender, age, centre, smoking status, alcohol
intake and physical activity.




















































wb Logarithmically transformed before linear regression analysis.
ignificant association between the presence of depressive symp-
oms and these two surrogates of insulin sensitivity.
Table 3 presents the results of the regression analysis includ-
ng insulin-secretion parameters. Depressive symptoms were not
elated to the beta-cell glucose sensitivity component. However,
ignificant depressive symptoms were statistically significantly
elated to the potentiation factor ratio although, after adjusting
or potential confounders (gender, age and centre), this associ-
tion was no longer significant. The addition of the potential
ediators also had no further effects on this association.
As for beta-cell rate sensitivity, multinominal regression anal-
ses showed that subjects with significant depressive symptoms
ere more likely to be in the lowest quartile of beta-cell rate
ensitivity compared with the highest quartile [odds ratio (OR):
.04, 95% CI: 1.16–3.60; P  = 0.01, fully adjusted analyses]. This
uggests that the beta-cell rate sensitivity is lower in depressed
eople. As shown in Table 3, the presence of significant depres-
ive symptoms appeared to be related to a lower insulinogenic
ndex in unadjusted analyses. However, after adjusting for the
onfounders, this association was no longer significant.
.1. Sensitivity  analyses
When the depression score was used instead of the binary
ariable for depression, the associations between depression
nd insulin sensitivity/secretion were comparable except for the
ssociation with OGIS. The CES-D score was weakly related
o a lower OGIS (beta = −0.06; P  = 0.037). Also, excluding par-
icipants who used psychoactive drugs (n  = 56) and those with
asting plasma glucose ≥  7.0 mmol/L and/or 2-h plasma glu-
ose ≥  11.1 mmol/L (n  = 14) from the present analyses did not
aterially affect the associations between significant depressive




tFig. 1 shows the prevalence of significant depressive symp-
oms by quartiles of each primary outcome parameter studied
fter adjusting for gender. The graphs show that the prevalence
f significant depressive symptoms did not differ across quartiles
f OGIS and beta-cell glucose sensitivity. On the other hand, the
revalence of depressive symptoms was significantly lower in
he highest quartiles of potentiation factor ratio and beta-cell rate
ensitivity.
. Discussion
In this relatively healthy sample of men and women aged 30
o 64 years, the presence of significant depressive symptoms was
ot related to measures of insulin sensitivity, but tended to be
eakly related to some indices of insulin secretion. Depressive
ymptoms were related to a slightly reduced first-phase insulin
esponse during the OGTT, as indicated by the insulinogenic
ndex, although this association disappeared after adjusting for
otential confounders. In addition, depressive symptoms were
lso related to lower rate sensitivity in response to glucose and
 decreased potentiation factor ratio.
In the present study, no significant association was observed
etween depressive symptoms and surrogate measures of insulin
ensitivity. This is consistent with some studies [17,18,20], but
ontrary to others [11–16]. Furthermore, a recent meta-analysis
ould find no greater prevalence of depression in patients with
mpaired glucose metabolism (impaired fasting glucose and
mpaired glucose tolerance combined) compared with people
ith normal glucose metabolism [36]. One explanation for theack of association in our study could be related to our sample,
hich comprised relatively young Caucasians who may have
ad more adequate levels of insulin sensitivity and secretion
han those included in other studies. Caucasians are known to
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Table 3
Linear regression analyses of the association of depression with insulin-secretion parameters.
Outcome Depression Bb (95% CI)  P
Beta-cell glucose sensitivitya (n = 925)
Unadjusted −0.021 (−0.070, 0.029) −0.027 0.416
Model 1 −0.032 (−0.082, 0.017) −0.042 0.203
Model 2 −0.030 (−0.080, 0.020) −0.039 0.234
Model 3 −0.006 (−0.053, 0.041) −0.008 0.793
Model 4 −0.004 (−0.051, 0.044) −0.005 0.878
Model 5 −0.004 (−0.052, 0.043) −0.006 0.856
Model 6 −0.006 (−0.053, 0.042) −0.007 0.816
Potentiation factor ratioa (n = 925)
Unadjusted −0.043 (−0.084, −0.001) −0.066 0.045
Model 1 −0.052 (−0.094, −0.010) −0.080 0.015
Model 2 −0.054 (−0.096, −0.012) −0.084 0.011
Model 3 −0.037 (−0.078, 0.003) −0.058 0.070
Model 4 −0.034 (−0.075, 0.006) −0.053 0.097
Model 5 −0.034 (−0.075, 0.006) −0.053 0.096
Model 6 −0.034 (−0.074, 0.007) −0.052 0.105
Insulinogenic indexa (n = 919)
Unadjusted −0.059 (−0.114, −0.003) −0.069 0.038
Model 1 −0.066 (−0.122, −0.010) −0.077 0.021
Model 2 −0.063 (−0.118, −0.008) −0.074 0.026
Model 3 −0.044 (−0.100, 0.012) −0.051 0.124
Model 4 −0.036 (−0.092, 0.021) −0.042 0.215
Model 5 −0.034 (−0.090, 0.023) −0.039 0.244
Model 6 −0.037 (−0.094, 0.019) −0.044 0.193
Model 7 −0.039 (−0.093, 0.014) −0.046 0.152
Model 1: adjusted for gender; Model 2: adjusted for gender and age; Model 3: adjusted for gender, age and centre; Model 4: adjusted for gender, age, centre and
smoking status; Model 5: adjusted for gender, age, centre, smoking status and alcohol intake; Model 6: adjusted for gender, age, centre, smoking status, alcohol














































ra Logarithmically transformed before linear regression analysis.
b Unstandardized regression coefficient ( is the standardized regression coef
ave a lower risk of glucose intolerance and diabetes compared
ith other ethnic groups [37].
Both insulin sensitivity and insulin secretion are predictors of
hanges in glucose tolerance [21]. Compared with assessment of
nsulin sensitivity, assessing beta-cell function and insulin secre-
ion is relatively complex [29], as beta-cells have to adjust insulin
elease in an appropriate amount and time course in response to
cute changes in plasma glucose concentrations. Our present
tudy found that depressive symptoms were related to reduced
arly insulin-secretion levels, as indicated by a slightly lower
nsulinogenic index, and to reduced rate sensitivity. Reduced
arly insulin secretion is seen in diabetes patients [31]. Our
bservations are in contrast to the study of Okamura et al. [23],
hich showed that AIR was increased in patients with major
epression compared with controls. In addition, they showed
hat AIR decreased after antidepressant therapy in patients with
epression [23]. The reason for this discrepancy is unclear, but
ould be related to the use of different surrogates for early insulin
ecretion, and the study’s particular design and sample popu-
ation (patients diagnosed with major depressive disorder vs.
hose with increased depressive symptoms). Moreover, our study
howed that depressive symptoms were related to reduced poten-
iation of insulin secretion. The potentiation factor comprises
everal potentiating mechanisms such as prolonged exposure
o hyperglycaemia, non-glucose substrates, gastrointestinal hor-




ecretion, reduced potentiation is also seen in diabetes patients
31]. Thus, the observed relationship between depressive symp-
oms and markers of insulin secretion appears to be in the
ypothetical diabetes related direction.
Nevertheless, as studies are sparse and conflicting, more
nd larger studies are needed to investigate how depressive
ymptoms relate to insulin secretion in specific subgroups of
ndividuals.
Strengths of our study are its innovative character and the
arge number of participants from 14 European countries. The
tudy also looked at the association between depressive symp-
oms and various components of beta-cell functioning and, thus,
as a better reflection of the complexity of insulin secretion than
he single parameters used in previous studies.
Our present study also had several limitations. First, surrogate
easures were used for depression, and insulin sensitivity and
ecretion, as the gold-standard measures were not assessed dur-
ng the 3-year follow-up. However, these validated indices are
ommonly used in epidemiological studies, as the gold standards
re not always feasible. Second, our data were cross-sectional
nd, thus, no causal inferences could be made. Furthermore, it
ight be that only sustained elevated depressive symptoms are
elated to changes in insulin sensitivity and secretion. Future
ongitudinal studies are warranted to further explore the associ-
tions between depressive symptoms and insulin sensitivity and
ecretion. Third, whether adjusting for study centre is necessary






















Rig. 1. Prevalence of elevated depressive symptoms for each quartile of OGIS (
ensitivity and potentiation factor ratio (insulin secretion). Q1–4: quartiles 1 (l
earson’s Chi2 tests (P) and Mantel–Haenszel linear-by-linear association test (
eeds to be discussed, as it is likely that centres differ in mea-
ured and unmeasured characteristics despite using the same
election criteria for participants. However, although this may
ustify adjusting for centre in the analyses, it remains unclear as
o what exactly this statistical adjustment means.
In conclusion, cross-sectional analyses in our large-scale
ulticentre cohort study did not demonstrate a significant asso-
iation between elevated depressive symptoms and measures of
nsulin sensitivity. In this relatively healthy sample population,
epressive symptoms tended to be related to reductions in some
arameters of insulin secretion, although these associations were
eak.
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